local_hospital

DERMAPOLIS Medical Dermatology Center dr n.med. Edyta Gebska

Address
ulica sw. Barbary 14, 41-500 Chorzów, Poland

Immune System Diseases

The DERMAPOLIS Medical Dermatology Center focuses on immune‑mediated skin conditions, especially atopic dermatitis, evaluating new oral agents for safety and long‑term use.

  • Long‑term safety assessment of abrocitinib
  • Combination with topical therapies
  • Inclusion of adolescent and adult participants

This work supports the development of targeted therapies that modulate immune pathways, aiming to improve outcomes for patients with moderate to severe disease.

Skin and Connective Tissue Diseases

Research at the center also addresses the broader category of skin and connective tissue diseases, with a focus on innovative treatments for eczema severity.

  • Efficacy evaluation of BFB759
  • Use of EASI score as a primary endpoint
  • Gender‑balanced adult cohort

Findings are expected to expand therapeutic options and refine disease‑activity measurement for those living with chronic dermatitis.

Site Overview

assignment
3
connected trials
corporate_fare
3
sponsors
science
2
IMPs

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
2
Trials started 6–12 months ago
3
Total trials linked
Moderately Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
0
Sponsors (total)
3
Active sponsors
0

Sponsor Network

Top 10 by active trials.

No sponsors linked to active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 1 628 other sites in Poland

description
Trial volume
3
Outperforms 56% of sites
public
Therapeutic diversity
2areas
Outperforms 53% of sites
groups
Sponsor diversity
3sponsors
Outperforms 58% of sites

Therapeutic Area Benchmark — Poland

Select a therapeutic area to compare against other sites in Poland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Poland

Market Share

Country: Poland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in DERMAPOLIS Medical Dermatology Center dr n.med. Edyta Gebska

lock Showing 1 of 3 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-509 in Adults with Moderate to Severe Atopic DermatitisTriveni Bio Inc.Phase IINot RecruitingJan 2026

IMP list

lock Showing 1 of 2 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Abrocitinib1Unknown2018-10-102018-10-10

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.